Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases

Fineline Cube Jun 22, 2026
Company Deals

UCB Completes $2.2B Acquisition of Candid Therapeutics to Advance BCMA T-Cell Engager for Autoimmune Diseases

Fineline Cube Jun 18, 2026
Company Deals

Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline

Fineline Cube Jun 18, 2026
Company Deals

Xunfei Healthcare Partners with Sinar Mas Group to Deploy AI Medical Solutions Across Indonesia

Fineline Cube Jun 18, 2026
Company Deals

Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline

Fineline Cube Jun 18, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

CSPC Pharmaceutical’s Cosentyx Biosimilar Accepted for NMPA Review in China’s Competitive IL-17A Market

Fineline Cube Jun 22, 2026
Company Drug

CSPC Pharmaceutical Secures FDA Clearance for SYHX2008 Octreotide Biosimilar Clinical Trials in US Market

Fineline Cube Jun 22, 2026
Company Drug

Dizal’s Sunvozertinib NDA Accepted for Review by China’s NMPA

Fineline Cube Jan 11, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...

Company Drug

HighTide Therapeutics Doses First Patient in Phase IIb Study for HTD1801 in NASH

Fineline Cube Jan 11, 2023

Shenzhen-based HighTide Therapeutics Inc. has announced that the first patient has been dosed in a...

Drug

MSD Submits Initial Quotation for Molnupiravir in China Amid New COVID-19 Rules

Fineline Cube Jan 11, 2023

Under new rules specifically for the launch of COVID-19 therapeutics in China, US-based Merck Sharp...

Company Drug

Treadwell Therapeutics’ CFI-402257 Granted Fast-Track Status by FDA

Fineline Cube Jan 11, 2023

China-based clinical-stage biotech Treadwell Therapeutics has announced receiving fast-track status from the US Food and...

Policy / Regulatory

CDE Releases 66th Batch of Chemical Generic Reference Preparations

Fineline Cube Jan 11, 2023

The Center for Drug Evaluation (CDE) has released the 66th batch of chemical generic reference...

Company Drug

Jiangsu Kanion’s KYS202002A Greenlit for Clinical Study in Multiple Myeloma

Fineline Cube Jan 11, 2023

China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving approval from the National...

Company Deals

Gaoling Medical Secures Funding for Infrared Thermotherapy Technology

Fineline Cube Jan 11, 2023

Gaoling Medical, a Hangzhou-based developer of systemic infrared thermotherapy technology, has raised an undisclosed amount...

Company Drug

Yiling Pharmaceutical’s BIO-008 Accepted for Review by China’s NMPA

Fineline Cube Jan 11, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...

Company Deals

Sino Biopharmaceutical Secures Rights to Biosimilar of Amgen’s Xgeva in China

Fineline Cube Jan 11, 2023

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary CP Pharmaceutical Qingdao has...

Company Deals

CanSino Biologics to Issue GDRs on SWX Swiss Exchange to Boost Globalization

Fineline Cube Jan 11, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced plans to issue an undisclosed amount...

Company Drug

Luye Pharma Launches Named Patient Program for Lurbinectedin in Hong Kong

Fineline Cube Jan 11, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the launch of a Named Patient Program...

Company Drug

Innovent Biologics Doses First Patient in Phase III Study for Mazdutide

Fineline Cube Jan 10, 2023

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient has been dosed...

Policy / Regulatory

China Meheco Keyi Pharma’s Ganciclovir Loses VBP Bid After Inspection Failure

Fineline Cube Jan 10, 2023

The national drug alliance procurement office has released a notification indicating that China Meheco Keyi...

Policy / Regulatory

NMPA Releases 63rd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Jan 10, 2023

The National Medical Products Administration (NMPA) has released the 63rd batch of reference drugs for...

Company Drug

Cosunter’s COVID-19 Drug GST-HG171 Shows Superior Efficacy in Trial

Fineline Cube Jan 10, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced positive results from an investigator-initiated...

Company Drug

Fosun Foundation Donates COVID-19 Therapy Azvudine to Rural China

Fineline Cube Jan 10, 2023

The Fosun Foundation, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Henan...

Policy / Regulatory

NMPA Approves Expanded Production for COVID-19 Symptom Treatments

Fineline Cube Jan 10, 2023

The National Medical Products Administration (NMPA) has approved filings from multiple companies to expand manufacturing...

Company Drug

Roche’s Glofitamab and Dizal’s Sunvozertinib Enter Priority Review

Fineline Cube Jan 10, 2023

The Center for Drug Evaluation (CDE) website indicates that Swiss giant Roche’s (SWX: ROG) glofitamab...

Company Deals

Yinjia Biosciences Raises RMB 100 Million in Series A Financing Round

Fineline Cube Jan 10, 2023

Yinjia Biosciences, a Shanghai-based developer of protein reagents and diagnostic products, has reportedly raised close...

Policy / Regulatory

China Optimizes Medical Insurance Policies for COVID-19 Treatment

Fineline Cube Jan 10, 2023

The National Healthcare Security Administration (NHSA), Ministry of Finance, National Health Commission, and Chinese Center...

Posts pagination

1 … 595 596 597 … 686

Recent updates

  • CSPC Pharmaceutical’s Cosentyx Biosimilar Accepted for NMPA Review in China’s Competitive IL-17A Market
  • CSPC Pharmaceutical Secures FDA Clearance for SYHX2008 Octreotide Biosimilar Clinical Trials in US Market
  • Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)
  • Johnson & Johnson Secures Second NMPA Approval for Akeega in BRCA2-Mutated Metastatic Prostate Cancer Following AMPLITUDE Trial Success
  • Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical’s Cosentyx Biosimilar Accepted for NMPA Review in China’s Competitive IL-17A Market

Company Drug

CSPC Pharmaceutical Secures FDA Clearance for SYHX2008 Octreotide Biosimilar Clinical Trials in US Market

Others

Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)

Company Drug

Johnson & Johnson Secures Second NMPA Approval for Akeega in BRCA2-Mutated Metastatic Prostate Cancer Following AMPLITUDE Trial Success

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.